Notably, FDA-approved monoclonal antibodies, such as etrolizumab, have been deployed to obstruct CD11a units and ITGB7 (integrin subunit beta 7) in inflammatory diseases such as severe plaque psoriasis, Crohn’s disease or ulcerative colitis, respectively (46, 47). This evidence concerns the gene ITGB7 and ulcerative colitis.